Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial

被引：43

作者：

Li, Ning ^{[1
]}

Zhang, Youzhong ^{[2
]}

Wang, Jing ^{[3
]}

Zhu, Jianqing ^{[4
]}

Wang, Li ^{[5
]}

Wu, Xiaohua ^{[6
]}

Yao, Desheng ^{[7
]}

Wu, Qiang ^{[8
]}

Liu, Jihong ^{[9
]}

Tang, Junying ^{[10
]}

Yin, Rutie ^{[11
,12
]}

Lou, Ge ^{[13
]}

An, Ruifang ^{[14
]}

Zhang, Guonan ^{[15
]}

Xia, Xiaoping ^{[16
]}

Li, Qingshui ^{[17
]}

Zhu, Yaping ^{[18
]}

Zheng, Hong ^{[19
]}

Yang, Xinfeng ^{[20
]}

Hu, Yuanjing ^{[21
]}

Zhang, Xin ^{[22
]}

Hao, Min ^{[23
]}

Huang, Yi ^{[24
]}

Lin, Zhongqiu ^{[25
]}

Wang, Dong ^{[26
]}

Guo, Xiaoqing ^{[27
]}

Yao, Shuzhong ^{[28
]}

Wan, Xiaoyun ^{[29
]}

Zhou, Huaijun ^{[30
]}

Yao, Liangqing ^{[31
]}

Yang, Xielan ^{[32
]}

Cui, Heng ^{[33
]}

Meng, Yuanguang ^{[34
]}

Zhang, Songling ^{[35
]}

Qu, Jing ^{[36
]}

Zhang, Ben ^{[36
]}

Zou, Jianjun ^{[36
]}

Wu, Lingying ^{[1
]}

机构：

[1] Chinese Acad Med Sci, Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr,Natl Clin Res Ctr Canc, Beijing, Peoples R China

[2] Shandong Univ, Qilu Hosp, Jinan, Peoples R China

[3] Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp, Hunan Canc Hosp, Changsha, Peoples R China

[4] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Hangzhou, Peoples R China

[5] Zhengzhou Univ, Henan Canc Hosp, Affiliated Canc Hosp, Zhengzhou, Peoples R China

[6] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China

[7] Guangxi Med Univ Canc Hosp, Nanning, Peoples R China

[8] Jiangsu Canc Hosp, Nanjing, Peoples R China

[9] Sun Yat Sen Univ Canc Ctr, Guangzhou, Peoples R China

[10] Chongqing Med Univ, Affiliated Hosp 1, Chongqing, Peoples R China

[11] Sichuan Univ, West China Second Univ Hosp, Chengdu, Peoples R China

[12] Sichuan Univ, West China Univ Hosp 2, Minist Educ, Key Lab Obstet & Gynecol & Pediat Dis & Birth Def, Chengdu, Peoples R China

[13] Harbin Med Univ Canc Hosp, Harbin, Peoples R China

[14] Xi An Jiao Tong Univ, Affiliated Hosp 1, Xian, Peoples R China

[15] Sichuan Canc Hosp, Chengdu, Peoples R China

[16] Anhui Prov Canc Hosp, Hefei, Peoples R China

[17] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Jinan, Peoples R China

[18] Shanghai Gen Hosp, Shanghai, Peoples R China

[19] Beijing Canc Hosp, Beijing, Peoples R China

[20] Jiangxi Canc Hosp, Nanchang, Jiangxi, Peoples R China

[21] Tianjin Cent Hosp Gynecol Obstet, Tianjin, Peoples R China

[22] Liaoning Canc Hosp & Inst, Shenyang, Peoples R China

[23] Shanxi Med Univ, Hosp 2, Taiyuan, Peoples R China

[24] Hubei Canc Hosp, Wuhan, Peoples R China

[25] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China

[26] Chongqing Univ Canc Hosp, Chongqing, Peoples R China

[27] Shanghai First Matern & Infant Hosp, Shanghai, Peoples R China

[28] Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou, Peoples R China

[29] Zhejiang Univ, Womans Hosp, Sch Med, Hangzhou, Peoples R China

[30] Nanjing Univ Med Sch, Affiliated Hosp, Nanjing Drum Tower Hosp, Nanjing, Peoples R China

[31] Fudan Univ, Obstet & Gynecol Hosp, Shanghai, Peoples R China

[32] Yunnan Canc Hosp, Kunming, Yunnan, Peoples R China

[33] Peking Univ Peoples Hosp, Beijing, Peoples R China

[34] Peoples Liberat Army Gen Hosp, Beijing, Peoples R China

[35] Jilin Univ, Bethune Hosp 1, Changchun, Peoples R China

[36] Jiangsu Hengrui Pharmaceut Co Ltd, Shanghai, Peoples R China

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 22期

关键词：

CANCER; PROGRESSION; INHIBITOR; SURVIVAL;

D O I：

10.1200/JCO.21.01511

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PURPOSE This phase III trial aimed to explore the efficacy and safety of fuzuloparib (formerly fluzoparib) versus placebo as a maintenance treatment after response to second- or later-line platinum-based chemotherapy in patients with high-grade, platinum-sensitive, recurrent ovarian cancer. PATIENTS AND METHODS Patients with platinum-sensitive, recurrent ovarian cancer previously treated with at least two platinum-based regimens were assigned (2:1) to receive fuzuloparib (150 mg, twice daily) or matching placebo for 28-day cycles. The primary end points were progression-free survival (PFS) assessed by blinded independent review committee (BIRC) in the overall population and PFS by BIRC in the subpopulation with germline BRCA 1/2 mutation. RESULTS Between April 30, 2019, and January 10, 2020, 252 patients were randomly assigned to the fuzuloparib (n = 167) or placebo (n = 85). As of July 1, 2020, the median PFS per BIRC assessment in the overall population was significantly improved with fuzuloparib treatment (hazard ratio [HR], 0.25; 95% CI, 0.17 to 0.36; one-sided P < .0001) compared with that with placebo. The HR derived from a prespecified subgroup analysis showed a consistent trend of benefit in patients with germline BRCA 1/2 mutations (HR, 0.14; 95% CI, 0.07 to 0.28) or in those without mutations (HR, 0.46; 95% CI, 0.29 to 0.74). The most common grade >= 3 treatment-emergent adverse events reported in the fuzuloparib group were anemia (25.1%), decreased platelet count (16.8%), and decreased neutrophil count (12.6%). Only one patient (0.6%) discontinued fuzuloparib because of treatment-related toxicity (concurrent decreased white blood cell count and neutrophil count). CONCLUSION Fuzuloparib as maintenance therapy achieved a statistically significant and clinically meaningful improvement in PFS for patients with platinum-sensitive, recurrent ovarian cancer versus placebo, regardless of germline BRCA 1/2 mutation, and showed a manageable safety profile.

引用

页码：2436 / +

页数：18

共 50 条

[21] Maintenance nifedipine therapy for preterm symptomatic placenta previa: A randomized, multicenter, double-blind, placebo-controlled trial
Verspyck, Eric
de Vienne, Claire
Muszynski, Charles
Bubenheim, Michael
Chanavaz-Lacheray, Isabella
Dreyfus, Michel
Deruelle, Philippe
Benichou, Jacques
PLOS ONE, 2017, 12 (03):
[22] A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse
Vergote, Ignace
Armstrong, Deborah
Scambia, Giovanni
Teneriello, Michael
Sehouli, Jalid
Schweizer, Charles
Weil, Susan C.
Bamias, Aristotelis
Fujiwara, Keiichi
Ochiai, Kazunori
Poole, Christopher
Gorbunova, Vera
Wang, Wenquan
O'Shannessy, Daniel
Herzog, Thomas J.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (19) : 2271 - +
[23] A randomized, double-blind, placebo-controlled multicenter phase 3 trial of niraparib maintenance treatment in patients with advanced ovarian cancer following frontline chemotherapy
Martin, A. Gonzalez
Rojas, L. A.
Braly, P. S.
Barter, J.
O'Malley, D. M.
Oza, A. M.
Haggerty, A. F.
Vulsteke, C.
Provencher, D. M.
Graybill, W.
Li, Y.
Malinowska, I. A.
Mirza, M. R.
Vergote, I.
Pothuri, B.
Monk, B. J.
ANNALS OF ONCOLOGY, 2017, 28
[24] Pentoxifylline in ALS: A double-blind, randomized, multicenter, placebo-controlled trial
Levin, B
Thompson, JLP
Levy, G
Mitsumoto, H
Kaufmann, P
NEUROLOGY, 2006, 66 (11) : 1786 - 1786
[25] Pentoxifylline in ALS - A double-blind, randomized, multicenter, placebo-controlled trial
Meininger, V
Asselain, B
Guillet, P
Leigh, PN
Ludolph, A
Lacomblez, L
Robberecht, W
NEUROLOGY, 2006, 66 (01) : 88 - 92
[26] Enoxaparin for prevention of unexplained recurrent miscarriage: a multicenter randomized double-blind placebo-controlled trial
Pasquier, Elisabeth
de Saint Martin, Luc
Bohec, Caroline
Chauleur, Celine
Bretelle, Florence
Marhic, Gisele
Le Gal, Gregoire
Debarge, Veronique
Lecomte, Frederic
Denoual-Ziad, Christine
Lejeune-Saada, Veronique
Douvier, Serge
Heisert, Michel
Mottier, Dominique
BLOOD, 2015, 125 (14) : 2200 - 2205
[27] A Phase II, Randomized, Double-blind, Placebo-controlled Multicenter Trial of Endostar in Patients With Metastatic Melanoma
Cui, Chuanliang
Mao, Lili
Chi, Zhihong
Si, Lu
Sheng, Xinan
Kong, Yan
Li, Siming
Lian, Bin
Gu, Kangsheng
Tao, Min
Song, Xin
Lin, Tongyu
Ren, Xiubao
Qin, Shukui
Guo, Jun
MOLECULAR THERAPY, 2013, 21 (07) : 1456 - 1463
[28] Prednisone for patients with recurrent implantation failure: study protocol for a double-blind, multicenter, randomized, placebo-controlled trial
Lu, Yao
Yan, Junhao
Liu, Jiayin
Tan, Jichun
Hong, Yan
Wei, Daimin
Chen, Zi-jiang
Sun, Yun
TRIALS, 2020, 21 (01)
[29] Efficacy of naproxen in patients with sciatica: multicenter, randomized, double-blind, placebo-controlled trial
Grovle, Lars
Hasvik, Eivind
Holst, Rene
Saetre, Anders
Brox, Jens Ivar
Mathiassen, Stale
Myhre, Kjersti
Holmgard, Thor Einar
Haugen, Anne Julsrud
PAIN, 2024, 165 (11) : 2606 - 2614
[30] A randomized, double-blind, multicenter, placebo-controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia
Hiroyoshi Ohta
Hiroshi Oka
Chie Usui
Masayuki Ohkura
Makoto Suzuki
Kusuki Nishioka
Arthritis Research & Therapy, 14

← 1 2 3 4 5 →